Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07569926 · ClinicalTrials.gov registry record · Phase 4
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
A Phase 4 study, sponsored by Blue Earth Diagnostics.
- Not yet
- Registry status
- Phase 4
- Development phase
- 142
- Enrollment target
NCT07569926: Clinical Trial Phase 4 study, sponsored by Blue Earth Diagnostics.
NCT07569926 is a Phase 4 study that has not yet begun recruiting, run by Blue Earth Diagnostics. The registered enrollment target is 142 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07569926, a Phase 4 study, has not yet begun recruiting, sponsored by Blue Earth Diagnostics.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 142 participants
- Enrollment target
Study Summary
The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
Interventions
- DRUG fluciclovine (18F)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2032-12-31 |
| Phase | Phase 4 |
What is known before NCT07569926 opens enrollment
NCT07569926 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which fluciclovine (18F) is the first listed.
NCT07569926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07569926 about?
NCT07569926 is a clinical study titled "Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence". The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
What is the current status of trial NCT07569926?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 142 participants. The study started on 2026-06-01. Estimated completion is 2032-12-31.
What interventions are being tested in trial NCT07569926?
The interventions under investigation include: fluciclovine (18F) (DRUG).
Who is sponsoring clinical trial NCT07569926?
This trial is sponsored by Blue Earth Diagnostics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07569926's enrollment target sits among peer trials
142 580th of 2000 higher than 1,421 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI